Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

BACKGROUND: Significant peripheral blood CD4+ T-cell depletion has been observed after a first cycle of rituximab, a monoclonal antibody directed against the CD20 antigen, which is currently used in rheumatoid arthritis. Of note, an absence of CD4+ T-cell decrease has been observed in non-responders...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Res Ther
Asıl Yazarlar: Lavielle, Matthieu, Mulleman, Denis, Goupille, Philippe, Bahuaud, Clément, Sung, Hsueh Cheng, Watier, Hervé, Thibault, Gilles
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5086062/
https://ncbi.nlm.nih.gov/pubmed/27793209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1152-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller